Stockreport

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF The Company's intellectual property now covers the combination, formulation, and method of use of PrimeCPatent protection extends through 2042, adding four additional ye [Read more]